Tissue Regenix Group PLC (LON:TRX)’s share price hit a new 52-week low during mid-day trading on Friday . The stock traded as low as GBX 8.50 ($0.11) and last traded at GBX 8.50 ($0.11), with a volume of 780,394 shares. The stock had previously closed at GBX 9.25 ($0.12).
Separately, Jefferies Group LLC reissued a “buy” rating and issued a GBX 39 ($0.51) price target on shares of Tissue Regenix Group PLC in a report on Friday, July 21st.
The company’s market capitalization is GBX 64.66 million. The firm has a 50-day moving average price of GBX 11.49 and a 200-day moving average price of GBX 13.21.
In related news, insider John Andrew Samuel acquired 2,000,000 shares of the business’s stock in a transaction dated Wednesday, August 9th. The stock was bought at an average price of GBX 10 ($0.13) per share, for a total transaction of £200,000 ($263,921.88).
WARNING: “Tissue Regenix Group PLC (TRX) Sets New 1-Year Low at $8.50” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2017/10/27/tissue-regenix-group-plc-trx-sets-new-1-year-low-at-8-50.html.
About Tissue Regenix Group PLC
Tissue Regenix Group plc is a medical technology company. The Company is engaged in the development of regenerative products to make replacement native tissue using biological (human and animal) tissues. It operates through Cardiac, Wound Care and Orthopaedics divisions. Its decellularisation (dCELL) technology removes deoxyribonucleic acid and other cellular material from tissue leaving an acellular scaffold, which is not rejected by the patient’s body.
Receive News & Ratings for Tissue Regenix Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tissue Regenix Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.